John Bielfeldt

Mr. John Bielfeldt

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Thomas Josef VoglThomas Josef Vogl
Thomas Josef Vogl
MBMichael Bialek
Michael Bialek
KEKatrin Eichler
Katrin Eichler
RHRenate Hammerstingl
Renate Hammerstingl
JBJohn Bielfeldt
John Bielfeldt
Hamzah AdwanHamzah Adwan
Hamzah Adwan
The aim of this study was to evaluate treatment of osteoid osteomas using bipolar radiofrequency ablation (RFA) and patients’ quality of life before and after therapy. We retrospectively evaluated patients who underwent bipolar RFA of osteoid osteomas between 2001 and 2016. We assessed patients’ symptoms before and after treatment (four weeks after treatment and long-term) using a questionnaire including severity and quality of pain on a 10-point scale (1 = no pain, 10 = severe pain), motion restrictions, pain-related sleep disorders, and necessary pain medication. In addition, we evaluated technical success, complications, hospitalization length, and patients’ satisfaction with treatment. This study included 62 patients (43 [69.4%] males, 26.2 ± 13.2 years). Average nidus size was 5.7 ± 2.6 mm. The rate of technical success was 100%. All RFAs were performed without any complications. One patient showed a recurrence, resulting in a recurrence rate of 1.6%, which was successfully treated by another session of RFA. Average hospitalization length was 1.5 ± 0.5 days. A total of 36 patients (58.1%) participated in the questionnaire, reporting an average pain severity of 8.2 ± 1.6 before RFA compared to 3.4 ± 3.0 four weeks after and an average of 2.1 ± 2.3, 6.6 years after therapy, (both p < 0.001). After therapy, 31 (86.1%) patients had no pain. The majority of patients (n = 34, 94.4%) had reduced or absent motion restriction after therapy (p < 0.001). Patient satisfaction rate was 91.7%. In conclusion, bipolar RFA is a safe and effective treatment modality for osteoid osteomas and improves quality of life by reducing pain severity and motion restrictions.

28 June 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Thomas Josef VoglThomas Josef Vogl
Thomas Josef Vogl
JBJohn Bielfeldt
John Bielfeldt
UKUlrich Kübler
Ulrich Kübler
Hamzah AdwanHamzah Adwan
Hamzah Adwan
This study shall retrospectively evaluate the efficacy and safety of liquid-nitrogen based CT-guided cryoablation (CA) as a minimal-invasive technique for the curative treatment of primary breast cancer. A total of 45 female patients with 56 tumors were treated by CT-guided CA in analgosedation as an outpatient procedure. We used a liquid-nitrogen based system with a single cryoprobe and performed two freeze cycles with an intermediate thawing. The mean tumor diameter was 1.6 ± 0.7 cm. Follow-up was conducted via contrast-enhanced MR images of the breast. No complications were observed in all 56 ablations. Initial complete ablation was achieved in 100% of cases. Four cases of local tumor progression were reported, resulting in a rate of 8.9%, and 6 cases of intramammary distant recurrence at a rate of 13.3%. The extramammary tumor progression was observed in 7 patients at a rate of 15.6%. The mean overall survival was 4.13 years (95% CI: 3.7–4.5). The mean overall progression-free survival was 2.5 years (95% CI: 1.8–3.2) and the mean local progression-free survival was 2.9 years (95% CI: 2.3–3.6). Cryoablation is a safe and effective treatment for primary breast cancer tumors, which can be performed in analgosedation and as an outpatient procedure. However, potential for improvement exists and further evidence is necessary.

14 May 2025 in Journal Of Neuroradiology
Verified
Journal Article
Open access
TVThomas J. Vogl
Thomas J. Vogl
LSLeon Vincent Stein
Leon Vincent Stein
CRClaus Rödel
Claus Rödel
JBJohn Bielfeldt
John Bielfeldt
Hamzah AdwanHamzah Adwan
Hamzah Adwan
To retrospectively analyze the safety and efficacy of intra-arterial chemoperfusion (IAC) for symptomatic patients with recurrent or post-therapeutic progressive primary malignant brain tumors in regard to safety, survival and therapy response as a palliative treatment. Thirty-nine patients (24 men, 15 women; mean age: 52) who were treated by IAC in 181 sessions (mean: 4.6 sessions/patient) were enrolled and evaluated in this study. Out of total 39 patients with primary malignant brain tumor, 27 (69%) were diagnosed with glioblastoma. The overall survival (OS) was calculated using the Kaplan-Meier method. Therapy response was determined according to RECIST 1.1. All IAC treatments were performed without major adverse events or treatment-related deaths. The median OS time was 10.3 months (95%CI: 0.6 - 19.9). The median PFS time was 5.9 months (95%CI: 3.6 - 8.3). The rate of partial response was 10.8% (4/37) and stable disease was achieved in 56.8% (21/37) of patients. Progressive disease was observed in 32.4% of cases (12/37). There were no cases of complete response. In two cases RECIST could not be analyzed due to loss of radiological follow-up. This study could show that IAC may serve as a safe palliative strategy for symptomatic patients with recurrent or post-therapeutic progressive primary malignant brain tumors.

29 May 2025 in Radiology Case Reports
Verified
Journal Article
Open access
TVThomas J. Vogl
Thomas J. Vogl
CPCarolyn Enam Pi-Bansa
Carolyn Enam Pi-Bansa
KOKyriakos Oikonomou
Kyriakos Oikonomou
JBJohn Bielfeldt
John Bielfeldt
Hamzah AdwanHamzah Adwan
Hamzah Adwan
Hepatic artery aneurysms (HAAs) are rare vascular abnormalities, accounting for 20% of all visceral arterial aneurysms. Nontraumatic HAAs are often asymptomatic and are typically discovered incidentally during imaging for unrelated conditions. However, they pose a significant risk of rupture, which can lead to life-threatening hemorrhaging. We present the case of a 65-year-old male with an asymptomatic saccular aneurysm of the proper hepatic artery diagnosed incidentally on CT scan. Further cross-sectional imaging confirmed the diagnosis and revealed no evidence of rupture. The patient underwent successful interventional endovascular repair using a covered stent under local anesthesia. This case emphasizes the use of minimally invasive techniques of interventional radiology in the management of complex vascular pathologies.

27 September 2024 in Medicina
Verified
Journal Article
Open access
PDF file
Thomas Josef VoglThomas Josef Vogl
Thomas Josef Vogl
ANAndreea-Ioana Nica
Andreea-Ioana Nica
CBChristian Booz
Christian Booz
Leona S. AlizadehLeona S. Alizadeh
Leona S. Alizadeh
Sven BeckerSven Becker
Sven Becker
Hamzah AdwanHamzah Adwan
Hamzah Adwan
Background and Objectives: This study aimed to evaluate the tumor response relating to and survival benefit of transarterial chemoperfusion (TACP) and transarterial chemoembolization (TACE) in the treatment of patients with unresectable gynecologic tumors who are intolerant of or have a suboptimal response to chemotherapy and radiotherapy. Materials and Methods: Between January 2000 and October 2023, 75 patients diagnosed with gynecologic tumors underwent 213 TACP and 154 TACE procedures. Of these, 33 patients were treated with TACP, 20 were treated with TACE, and 22 received a combination of both therapies. A retrospective evaluation of local tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) was conducted, and survival rates were determined using the Kaplan–Meier estimator. Results: Of the total 75 patients, 50 (67%) maintained a stable course of disease until the completion of therapy, 10 (13%) had a partial response, 2 (3%) had a complete response following thermal ablation, and 13 (17%) experienced progression. Furthermore, a 6% reduction in the sum of the longest diameters and an 8% reduction in tumor volume were observed. The median overall survival was 16.15 months, while the median progression-free survival was 13.19 months. Conclusions: TACP and TACE are potential treatment options for local tumor control in patients with unresectable gynecologic tumors who are intolerant of or show a poor response to chemotherapy and radiotherapy. However, further investigation and adjustment of treatment protocols are required to improve therapy response and survival outcomes.